Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + Nivolumab vs Nivolumab in Advanced Melanoma
NCT03470922Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 25
01
Overview
A Phase 3 trial of relatlimab in melanoma, sponsored by Bristol Myers Squibb. Started Apr 2018; status: active, not recruiting.
02
Drugs
relatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03470922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03470922.